Skip to main content

Advertisement

SpringerLink
Log in

Late effects of therapy for Hodgkin’s lymphoma

  • Published:
Current Hematologic Malignancy Reports Aims and scope Submit manuscript

Abstract

Hodgkin’s lymphoma exemplifies a malignancy in which the benefits and risks of therapy are strikingly obvious: although 70% to 95% of patients survive (depending on disease stage), the late adverse health effects of therapy compromise quality of life and can be fatal. We review the broad range of these potential effects. Although secondary malignancies and cardiovascular disease are the most life-threatening sequelae, pulmonary, endocrine, and reproductive effects can also substantially compromise quality of life. Specific sequelae are not distributed evenly among survivors but depend on characteristics of the patient and treatment. Recent risk-adapted treatment protocols have eliminated or reduced the use of therapies most associated with adverse effects, such as alkylating agents, anthracyclines, and radiotherapy. Early studies suggest that these strategies reduce the frequency and severity of adverse effects, but additional follow-up of patients is necessary to confirm improved outcomes. Recognition of adverse effects has also led to recommendations for screening.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Ries LAG, Eisner MP, Kosary C, et al.: SEER Cancer Statistics Review, 1973–2001. Bethesda, MD: National Cancer Institute; 2004.

    Google Scholar 

  2. Mauch P, Kalish LA, Marcus KC, et al.: Long-term survival in Hodgkin’s disease: relative impact of mortality, second tumors, infection, and cardiovascular disease. Cancer J Sci Am 1995, 1:33–42.

    PubMed  CAS  Google Scholar 

  3. van Leeuwen FE, Klokman WJ, Veer MB, et al.: Long-term risk of second malignancy in survivors of Hodgkin’s disease treated during adolescence or young adulthood. J Clin Oncol 2000, 18:487–497.

    PubMed  Google Scholar 

  4. Bhatia S, Yasui Y, Robison LL, et al.: High risk of subsequent neoplasms continues with extended follow-up of childhood Hodgkin’s disease: report from the Late Effects Study Group. J Clin Oncol 2003, 21:4386–4394.

    Article  PubMed  Google Scholar 

  5. Ng AK, Bernardo MV, Weller E, et al.: Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factors. Blood 2002, 100:1989–1996.

    Article  PubMed  CAS  Google Scholar 

  6. Chronowski GM, Wilder RB, Levy LB, et al.: Second malignancies after chemotherapy and radiotherapy for Hodgkin disease. Am J Clin Oncol 2004, 27:73–80.

    Article  PubMed  CAS  Google Scholar 

  7. Dores GM, Metayer C, Curtis RE, et al.: Second malignant neoplasms among long-term survivors of Hodgkin’s disease: a population-based evaluation over 25 years. J Clin Oncol 2002, 3484–3494.

  8. van Leeuwen FE, Klokman WJ, Stovall M, et al.: Roles of radiation dose, chemotherapy, and hormonal factors in breast cancer following Hodgkin’s disease. J Natl Cancer Inst 2003, 95:971–980.

    Article  PubMed  Google Scholar 

  9. Travis LB, Gospodarowicz M, Curtis RE, et al.: Lung cancer following chemotherapy and radiotherapy for Hodgkin’s disease. J Natl Cancer Inst 2002, 94:182–192.

    PubMed  Google Scholar 

  10. Hancock SL, Tucker MA, Hoppe RT: Breast cancer after treatment of Hodgkin’s disease. J Natl Cancer Inst 1993, 85:25–31.

    Article  PubMed  CAS  Google Scholar 

  11. Bhatia S, Robison LL, Oberlin O, et al.: Breast cancer and other second neoplasms after childhood Hodgkin’s disease. N Engl J Med 1996, 334:745–751.

    Article  PubMed  CAS  Google Scholar 

  12. Travis LB, Hill D, Dores GM, et al.: Cumulative absolute breast cancer risk for young women treated for Hodgkin lymphoma. J Natl Cancer Inst 2005, 97:1428–1437.

    Article  PubMed  Google Scholar 

  13. Kenney LB, Yasui Y, Inskip PD, et al.: Breast cancer after childhood cancer: a report from the Childhood Cancer Survivor Study. Ann Intern Med 2004, 141:590–597.

    PubMed  Google Scholar 

  14. Aisenberg AC, Finkelstein DM, Doppke KP, et al.: High risk of breast carcinoma after irradiation of young women with Hodgkin’s disease. Cancer 1997, 79:1203–1210.

    Article  PubMed  CAS  Google Scholar 

  15. Travis LB, Hill DA, Dores GM, et al.: Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease. JAMA 2003, 290:465–475.

    Article  PubMed  Google Scholar 

  16. Hill DA, Gilbert E, Dores GM, et al.: Breast cancer risk following radiotherapy for Hodgkin lymphoma: modification by other risk factors. Blood 2005, 106:3358–3365.

    Article  PubMed  CAS  Google Scholar 

  17. Albrektsen G, Heuch I, Kvale G: The short-term and long-term effect of a pregnancy on breast cancer risk: a prospective study of 802,457 parous Norwegian women. Br J Cancer 1995, 72:480–484.

    PubMed  CAS  Google Scholar 

  18. Adams MJ, Lipshultz SE: Pathophysiology of anthracycline-and radiation-associated cardiomyopathies: implications for screening and prevention. Pediatr Blood Cancer 2005, 44:600–606.

    Article  PubMed  Google Scholar 

  19. Hancock SL, Hoppe RT: Long-term complications of treatment and causes of mortality after Hodgkin’s disease. Semin Radiat Oncol 1996, 6:225–242.

    Article  PubMed  Google Scholar 

  20. Aleman BM, van den Belt-Dusebout AW, Klokman WJ, et al.: Long-term cause-specific mortality of patients treated for Hodgkin’s disease. J Clin Oncol 2003, 21:3431–3439.

    Article  PubMed  Google Scholar 

  21. Aleman BM, van den Belt-Dusebout AW, De Bruin ML, et al.: Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood 2007, 109:1878–1886.

    Article  PubMed  CAS  Google Scholar 

  22. Lee CK, Aeppli D, Nierengarten ME: The need for long-term surveillance for patients treated with curative radiotherapy for Hodgkin’s disease: University of Minnesota experience. Int J Radiat Oncol Biol Phys 2000, 48:169–179.

    Article  PubMed  CAS  Google Scholar 

  23. Hancock SL, Tucker MA, Hoppe RT: Factors affecting late mortality from heart disease after treatment of Hodgkin’s disease. JAMA 1993, 270:1949–1955.

    Article  PubMed  CAS  Google Scholar 

  24. Hancock SL, Donaldson SS, Hoppe RT: Cardiac disease following treatment of Hodgkin’s disease in children and adolescents. J Clin Oncol 1993, 11:1208–1215.

    PubMed  CAS  Google Scholar 

  25. Reinders JG, Heijmen BJ, Olofsen-van Acht MJ, et al.: Ischemic heart disease after mantlefield irradiation for Hodgkin’s disease in long-term follow-up. Radiother Oncol 1999, 51:35–42.

    Article  PubMed  CAS  Google Scholar 

  26. Boivin J-F, Hutchison G, Lubin J, Mauch P: Coronary artery disease mortality in patients treated for Hodgkin’s disease. Cancer 1992, 69:1241–1247.

    Article  PubMed  CAS  Google Scholar 

  27. Heidenreich PA, Schnittger I, Strauss HW, et al.: Screening for coronary artery disease after mediastinal irradiation for Hodgkin’s disease. J Clin Oncol 2007, 25:43–49.

    Article  PubMed  Google Scholar 

  28. Adams MJ, Lipsitz SR, Colan SD, et al.: Cardiovascular status in long-term survivors of Hodgkin’s disease treated with chest radiotherapy. J Clin Oncol 2004, 22:3139–3148.

    Article  PubMed  Google Scholar 

  29. Heidenreich PA, Hancock SL, Vagelos RH, et al.: Diastolic dysfunction after mediastinal irradiation. Am Heart J 2005, 150:977–982.

    Article  PubMed  Google Scholar 

  30. Iarussi D, Pisacane C, Indolfi P, et al.: Evaluation of left ventricular function in long-term survivors of childhood Hodgkin disease. Pediatr Blood Cancer 2005, 45:700–705.

    Article  PubMed  Google Scholar 

  31. Swerdlow AJ, Higgins CD, Smith P, et al.: Myocardial infarction mortality risk after treatment for Hodgkin disease: a collaborative British cohort study. J Natl Cancer Inst 2007, 99:206–214.

    Article  PubMed  Google Scholar 

  32. Bowers DC, McNeil DE, Liu Y, et al.: Stroke as a late treatment effect of Hodgkin’s disease: a report from the Childhood Cancer Survivor Study. J Clin Oncol 2005, 23:6508–6515.

    Article  PubMed  Google Scholar 

  33. Bilora F, Pietrogrande F, Petrobelli F, et al.: Is radiation a risk factor for atherosclerosis? An echo-color Doppler study on Hodgkin and non-Hodgkin patients. Tumori 2006, 92:295–298.

    PubMed  Google Scholar 

  34. Horning SJ, Adhikari A, Rizk N, et al.: Effect of treatment for Hodgkin’s disease on pulmonary function: results of a prospective study. J Clin Oncol 1994, 12:297–305.

    PubMed  CAS  Google Scholar 

  35. Friedman DL, Constine LS: Late effects of treatment for Hodgkin lymphoma. J Natl Comp Cancer Netw 2006, 4:249–257.

    Google Scholar 

  36. Martin WG, Ristow KM, Habermann TM, et al.: Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin’s lymphoma. J Clin Oncol 2005, 23:7614–7620.

    Article  PubMed  CAS  Google Scholar 

  37. Knobel H, Havard LJ, Brit LM, et al.: Late medical complications and fatigue in Hodgkin’s disease survivors. J Clin Oncol 2001, 19:3226–3233.

    PubMed  CAS  Google Scholar 

  38. Sklar C, Whitton J, Mertens A, et al.: Abnormalities of the thyroid in survivors of Hodgkin’s disease: data from the Childhood Cancer Survivor Study. J Clin Endocrinol Metab 2000, 85:3227–3232.

    Article  PubMed  CAS  Google Scholar 

  39. Metzger ML, Hudson MM, Somes GW, et al.: White race as a risk factor for hypothyroidism after treatment for pediatric Hodgkin’s lymphoma. J Clin Oncol 2006, 24:1516–1521.

    Article  PubMed  Google Scholar 

  40. Sklar CA, Mertens AC, Mitby P, et al.: Premature menopause in survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. J Natl Cancer Inst 2006, 98:890–896.

    Article  PubMed  Google Scholar 

  41. Chemaitilly W, Mertens AC, Mitby P, et al.: Acute ovarian failure in the Childhood Cancer Survivor Study. J Clin Endocrinol Metab 2006, 91:1723–1728.

    Article  PubMed  CAS  Google Scholar 

  42. Behringer K, Breuer K, Reineke T, et al.: Secondary amenorrhea after Hodgkin’s lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin’s Lymphoma Study Group. J Clin Oncol 2005, 23:7555–7564.

    Article  PubMed  Google Scholar 

  43. Loge JH, Abrahamsen AF, Ekeberg O, Kaasa S: Hodgkin’s disease survivors more fatigued than the general population. J Clin Oncol 1999, 17:253–261.

    PubMed  CAS  Google Scholar 

  44. Mols F, Vingerhoets AJ, Coebergh JW, et al.: Better quality of life among 10–15 year survivors of Hodgkin’s lymphoma compared to 5–9 year survivors: a population-based study. Eur J Cancer 2006, 42:2794–2801.

    Article  PubMed  Google Scholar 

  45. Hjermstad MJ, Fossa SD, Oldervoll L, et al.: Fatigue in long-term Hodgkin’s disease survivors: a follow-up study. J Clin Oncol 2005, 23:6587–6595.

    Article  PubMed  Google Scholar 

  46. Hjermstad MJ, Oldervoll L, Fossa SD, et al.: Quality of life in long-term Hodgkin’s disease survivors with chronic fatigue. Eur J Cancer 2006, 42:327–333.

    Article  PubMed  Google Scholar 

  47. Ng AK, Li S, Recklitis C, et al.: A comparison between long-term survivors of Hodgkin’s disease and their siblings on fatigue level and factors predicting for increased fatigue. Ann Oncol 2005, 16:1949–1955.

    Article  PubMed  CAS  Google Scholar 

  48. Donaldson SS, Link MP, Weinstein HJ, et al.: Final results of a prospective clinical trial with VAMP and low-dose involved-field radiation for children with low-risk Hodgkin’s disease. J Clin Oncol 2007, 25:332–337.

    Article  PubMed  CAS  Google Scholar 

  49. Chow LM, Nathan PC, Hodgson DC, et al.: Survival and late effects in children with Hodgkin’s lymphoma treated with MOPP/ABV and low-dose, extended-field irradiation. J Clin Oncol 2006, 24:5735–5741.

    Article  PubMed  CAS  Google Scholar 

  50. Children’s Oncology Group: Long-term follow-up guidelines for survivors of childhood, adolescent, and young adult cancers (Ver. 2.0, 2006). http://www.survivorshipguidelines.org/. Accessed March 2007.

  51. Saslow D, Boetes C, Burke W, et al.: American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin 2007, 57:75–89.

    Article  PubMed  Google Scholar 

  52. Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol In Adults: Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001, 285:2486–2497.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pediatrics, University of Miami Miller School of Medicine, P.O. Box 016820, Miami, FL, 33101, USA

    Steven E. Lipshultz MD

Authors
  1. Michael Jacob Adams MD, MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Louis S. Constine MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Steven E. Lipshultz MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Steven E. Lipshultz MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Adams, M.J., Constine, L.S. & Lipshultz, S.E. Late effects of therapy for Hodgkin’s lymphoma. Curr Hematol Malig Rep 2, 143–150 (2007). https://doi.org/10.1007/s11899-007-0020-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11899-007-0020-4

Keywords

Search

Navigation